Gemcitabine-oxaliplatin regimen: all 24 studies that test it
Page 1 of 1. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.
- A Phase II Study of Ivonescimab in Combination With GEMOX as Neoadjuvant and Conversion Therapy for Biliary Tract CancerRecruitingNCT07854600Phase 2
- Golidocitinib Combined With GemOx in RR PTCLNot yet recruitingNCT07279584Phase 2
- Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular CarcinomaRecruitingNCT06904170Phase 2/3
- A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.Not yet recruitingNCT06654947Phase 2
- A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCsRecruitingNCT06423170Phase 2
- Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBCRecruitingNCT06013943Phase 2
- Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell LymphomaNot yet recruitingNCT05381506Phase 2
- Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic CholangiocarcinomaRecruitingNCT03364530Phase 2
- A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTCCompletedNCT03092895Phase 2Results posted
- Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell LymphomaTerminatedNCT06941688Phase 2
- Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCATerminatedNCT06739252Phase 2
- First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAICTerminatedNCT06370663Phase 2
- Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract CancerActive, not recruitingNCT05156788Phase 2
- SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's LymphomaStatus unknownNCT04948788Phase 2
- A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell LymphomaTerminatedNCT04425070Phase 1/2
- SHR-1210 in Combination With GEMOX in Patients With Advanced BTCCompletedNCT03486678Phase 2
- Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular CarcinomaWithdrawnNCT02534337Phase 2/3
- Molecularly Tailored Therapy for Pancreas CancerCompletedNCT01888978Phase 2
- Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin-unfit Urothelial CarcinomaStatus unknownNCT01487915Phase 2
- GEMOX in Docetaxel-Refractory Castration-Resistant Prostate CancerCompletedNCT01487720Phase 2
- Gemcitabine/Oxaliplatin (GEMOX) With or Without Erlotinib (Tarceva) in Advanced Biliary Tract CarcinomaCompletedNCT01149122Phase 3
- Biliary Cancers: EGFR INhibitor, Gemcitabine and OxaliplatinCompletedNCT00552149Phase 2
- Gemox as First and Second Line Therapy in Unknown Primary CancerCompletedNCT00353145Phase 2
- Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00087802Phase 3